The pediatric ocular tumor retinoblastoma readily metastasizes, but these lesions can masquerade 17 as histologically similar pediatric small round blue cell tumors. Since 98% of retinoblastomas 18
confirmed that a temple mass was metastatic retinoblastoma. In a second patient, a rib mass 23 shared somatic copy number gains and losses with the primary tumor. For definitive diagnosis, 24 however, an RB1 mutation was needed, but heterozygous promoteràexon 11 deletion was the 25 only RB1 mutation detected in the primary tumor. We used a novel application of inverse PCR to 26 identify the deletion breakpoint. Subsequently, AS-PCR designed for the breakpoint confirmed 27 that the rib mass was metastatic retinoblastoma. These cases demonstrate that personalized 28 molecular testing can confirm retinoblastoma metastases and rule out a second primary cancer, 29 thereby helping to direct the clinical management. 30
Introduction 34
Retinoblastoma is the most common pediatric eye cancer with an incidence of 1/16000 to 35 18000 worldwide [1] . Retinoblastoma results from biallelic mutation of the RB1 gene 36 (OMIM:180200), with a rare exception [2] . One RB1 mutation is germline and heritable in 37 50% of patients [3] . Thousands (Figure 2A, B) . Our standard RB1 mutation detection workflow [14] identified a deletion, 116 promoteràexon 11, in the primary tumor. No second, tumor-specific RB1 mutation was found, 117 nor any constitutive RB1 mutation. The child was followed in clinic every three months. A year 118 later the child experienced night pains and fever, initially misdiagnosed as Kawasaki's disease7 until a paravertebral mass ( Figure 2C ) was detected on MRI; fine needle aspiration cytology 120 revealed a small round cell tumor ( Figure 2D ). The differential diagnosis included a second 121 primary such as Ewing's sarcoma, or metastatic retinoblastoma, which was considered unlikely 122 due to the absence of histopathological features indicating risk for metastases. Serial sections of 123 the whole eye again confirmed pT2a with focal choroidal invasion, not considered to indicate 124 high risk for metastasis. 125
Given the histopathologic uncertainty, we again employed molecular analysis to characterize this 126 mass. We analyzed DNA from the rib mass and the primary tumor for the "hotspot" copy 127 number change profile characteristic of retinoblastoma [16] . Both tumors shared the same pattern 128 of common copy number changes of retinoblastoma ( Figure 2E ). Moreover, aCGH of rib mass 129 DNA confirmed a pattern of genome-wide copy number changes consistent with those seen 130 commonly in retinoblastoma ( Figure 2F) [21]. This shared genomic "fingerprint" suggested that 131 the rib mass and the primary tumor shared the same origin. 132
Inverse PCR Identifies a Deletion Breakpoint 133
To monitor this tumor, the identity of the unique deletion breakpoint was needed to enable AS-134 PCR. aCGH confirmed a deletion of ≥238 kbp spanning the 5′ end of RB1 in the primary tumor 135 ( Figure 2G ). Due to wide spacing of aCGH oligonucleotide probes around the deletion, a higher-136 resolution approach was required to identify the precise deletion breakpoint. We turned to 137 inverse PCR for this task. Based on the known, flanking two-copy QM-PCR primer and aCGH 138 probe locations, we designed primers for inverse PCR ( Figure 2H ). These primers yielded a 2.6 139 kbp band specific to tumor DNA that had undergone ligation ( Figure 2I) . 140 8 The 3′ ends of both the 2.6 kbp inverse PCR product and a confirmatory 2.5 kbp nested PCR 141 product (data not shown) contained sequence that mapped to the RB1 gene, as far upstream as 142 g.71606. However, the 5′ ends of these PCR products mapped to sequence upstream of the 143 HNRNPA1L2 gene, confirming the breakpoint location. This gene lies ~4 Mbp telomeric of RB1, 144 suggesting an unbalanced inversion. Using the breakpoint sequence, we designed primers that 145 were specific for tumor DNA. This primer set could detect one part tumor DNA in 1000 parts 146 normal DNA (Figure 2J ), indicating a reasonably sensitive assay for minimal residual disease 147 detection. The patient's rib mass and pre-treatment bone marrow were both strongly positive, 148 while post-treatment bone marrow was negative ( Figure 2J ). With metastatic retinoblastoma 149 diagnosis confirmed, the child received systemic chemotherapy followed by high dose 150 chemotherapy with autologous BMT. The child remained in remission for 12 months, then brain 151 and meningeal recurrences reappeared. The child died 18 months after presentation with 152 metastasis, 30 months after initial retinoblastoma diagnosis. 153
Discussion 154
We describe two patients originally diagnosed with retinoblastoma who subsequently developed 155 additional tumors. After inconclusive histology, to ascertain if these were metastases, we 156 employed molecular genetic strategies, including a novel use of inverse PCR to develop an AS-157 PCR assay for the breakpoints of a large deletion. 158
In both cases, the RB1 mutation originally found in the eye tumor was also present in the 159 subsequent extraocular tumor, confirming that the disease was metastatic. In both cases, 160
anatomic pathology failed to indicate risk of metastasis; both tumors behaved in an unusually 161 aggressive manner that warrants further research. This report illustrates the value of innovative, 162 
